Francesca Briganti

Title: Francesca Briganti: Innovator in Cardiac Research

Introduction

Francesca Briganti is a prominent inventor based in Palo Alto, California. She has made significant contributions to the field of cardiac research, particularly in understanding heart conditions associated with RBM20 deficiency. Her innovative work has led to advancements in treatment methods and genetic screening.

Latest Patents

Francesca Briganti holds a patent for "Methods of treatment, genetic screening, and disease models for heart conditions associated with RBM20 deficiency." This patent discloses methods for treating heart conditions linked to RBM20 deficiency, including RBM20-dependent dilated cardiomyopathy and heart failure. The patent outlines the use of compounds that upregulate the expression of RBM20, such as all-trans retinoic acid. Additionally, it includes methods for genetic screening to detect the P633L mutation in RBM20, which helps identify individuals with a genetic predisposition to developing RBM20-dependent DCM. The patent also discusses induced pluripotent stem cell-derived cardiomyocytes (IPSC-CMs) for screening therapeutics aimed at treating RBM20-dependent DCM.

Career Highlights

Francesca Briganti has worked at esteemed institutions, including the European Molecular Biology Laboratory and Leland Stanford Junior University. Her career reflects a commitment to advancing medical research and improving patient outcomes through innovative solutions.

Collaborations

Francesca has collaborated with notable colleagues, including Lars Steinmetz and Han Sun. These partnerships have further enriched her research and contributed to the development of her patented methods.

Conclusion

Francesca Briganti's work exemplifies the intersection of innovation and medical research, particularly in the realm of cardiac health. Her contributions continue to pave the way for new treatments and genetic understanding of heart conditions.